News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ArQule, Inc. (ARQL) Release: Data Presented at European Cancer Congress Suggest Clinical Benefit of Tivantinib in Patients with MET High Non-Squamous Non-Small Cell Lung Cancer



9/30/2013 7:00:55 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Data presented at the European Cancer Congress demonstrated clinical benefits of treatment with the combination of tivantinib and erlotinib in patients with non-squamous, non-small cell lung cancer (NSCLC) whose tumors expressed high levels of MET protein (Abstract number 3410, MARQUEE: a randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib [ARQ 197] plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES